Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBIT (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBIT for 7 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 55.78% to -$23.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$156.4 million through Dec 2025, up 31.52% year-over-year, with the annual reading at -$156.4 million for FY2025, 31.52% up from the prior year.
  • EBIT for Q4 2025 was -$23.6 million at Pliant Therapeutics, up from -$28.3 million in the prior quarter.
  • The five-year high for EBIT was -$22.9 million in Q2 2021, with the low at -$62.0 million in Q3 2024.
  • Average EBIT over 5 years is -$39.7 million, with a median of -$39.7 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 308.2% in 2021, then skyrocketed 55.78% in 2025.
  • Over 5 years, EBIT stood at -$24.6 million in 2021, then crashed by 52.04% to -$37.4 million in 2022, then dropped by 25.77% to -$47.0 million in 2023, then fell by 13.36% to -$53.3 million in 2024, then surged by 55.78% to -$23.6 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$23.6 million, -$28.3 million, and -$45.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.